← All trials
NCT06309147
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2024
- Primary completion
- Feb 15, 2025
- Completion date
- Jul 15, 2025
- First posted
- Mar 13, 2024
- Last posted
- Mar 18, 2024
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Allyx TherapeuticsLead sponsor
- Michael J. Fox Foundation for Parkinson's ResearchCollaborator
- Duke UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.